194 related articles for article (PubMed ID: 35248947)
1. Epoxymicheliolide inhibits osteoclastogenesis and resists OVX-induced osteoporosis by suppressing ERK1/2 and NFATc1 signaling.
Long F; Chen R; Su Y; Liang J; Xian Y; Yang F; Lian H; Xu J; Zhao J; Liu Q
Int Immunopharmacol; 2022 Jun; 107():108632. PubMed ID: 35248947
[TBL] [Abstract][Full Text] [Related]
2. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities.
Liu Y; Wang C; Wang G; Sun Y; Deng Z; Chen L; Chen K; Tickner J; Kenny J; Song D; Zhang Q; Wang H; Chen Z; Zhou C; He W; Xu J
Theranostics; 2019; 9(16):4648-4662. PubMed ID: 31367247
[No Abstract] [Full Text] [Related]
3. Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway.
Wu L; Liang J; Li J; Xu Y; Chen J; Su Y; Xian Y; Wei J; Xu J; Zhao J; Liu Q; Yang Y
Eur J Pharmacol; 2022 May; 923():174908. PubMed ID: 35405113
[TBL] [Abstract][Full Text] [Related]
4. Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption.
Li S; Teguh D; Wu D; Liu L; Hu C; Yuan J; Inderjeeth CA; Xu J
J Cell Physiol; 2023 Aug; 238(8):1823-1835. PubMed ID: 37334837
[TBL] [Abstract][Full Text] [Related]
5. PDK2 Deficiency Prevents Ovariectomy-Induced Bone Loss in Mice by Regulating the RANKL-NFATc1 Pathway During Osteoclastogenesis.
Lee JM; Kim MJ; Lee SJ; Kim BG; Choi JY; Lee SM; Ham HJ; Koh JM; Jeon JH; Lee IK
J Bone Miner Res; 2021 Mar; 36(3):553-566. PubMed ID: 33125772
[TBL] [Abstract][Full Text] [Related]
6. Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
Chen D; Ye Z; Wang C; Wang Q; Wang H; Kuek V; Wang Z; Qiu H; Yuan J; Kenny J; Yang F; He J; Liu Y; Wang G; Zhang M; Zhang G; Wang J; Chen P; Xu J
Pharmacol Res; 2020 Sep; 159():104944. PubMed ID: 32454224
[TBL] [Abstract][Full Text] [Related]
7. Andrographolide Inhibits Ovariectomy-Induced Bone Loss via the Suppression of RANKL Signaling Pathways.
Wang T; Liu Q; Zhou L; Yuan JB; Lin X; Zeng R; Liang X; Zhao J; Xu J
Int J Mol Sci; 2015 Nov; 16(11):27470-81. PubMed ID: 26593901
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
9. Corylifol A protects against ovariectomized-induced bone loss and attenuates RANKL-induced osteoclastogenesis via ROS reduction, ERK inhibition, and NFATc1 activation.
Xu Y; Song D; Lin X; Peng H; Su Y; Liang J; Hai N; Zhao J; Liu Q
Free Radic Biol Med; 2023 Feb; 196():121-132. PubMed ID: 36649902
[TBL] [Abstract][Full Text] [Related]
10. MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL-Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway.
Wang Y; Li X; Zhou S; Li J; Zhu Y; Wang Q; Zhao F
Oxid Med Cell Longev; 2022; 2022():7727006. PubMed ID: 36148414
[TBL] [Abstract][Full Text] [Related]
11. Dihydrotanshinone I attenuates estrogen-deficiency bone loss through RANKL-stimulated NF-κB, ERK and NFATc1 signaling pathways.
Ma C; Mo L; Wang Z; Peng D; Zhou C; Niu W; Liu Y; Chen Z
Int Immunopharmacol; 2023 Oct; 123():110572. PubMed ID: 37572501
[TBL] [Abstract][Full Text] [Related]
12. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
[TBL] [Abstract][Full Text] [Related]
13. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
Chen G; Xu Q; Dai M; Liu X
Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
[TBL] [Abstract][Full Text] [Related]
14. Chaenomelis fructus inhibits osteoclast differentiation by suppressing NFATc1 expression and prevents ovariectomy-induced osteoporosis.
Kim M; Kim HS; Kim JH; Kim EY; Lee B; Lee SY; Jun JY; Kim MB; Sohn Y; Jung HS
BMC Complement Med Ther; 2020 Feb; 20(1):35. PubMed ID: 32024503
[TBL] [Abstract][Full Text] [Related]
15. miR-128 plays a critical role in murine osteoclastogenesis and estrogen deficiency-induced bone loss.
Shen G; Ren H; Shang Q; Zhang Z; Zhao W; Yu X; Tang J; Yang Z; Liang D; Jiang X
Theranostics; 2020; 10(10):4334-4348. PubMed ID: 32292498
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of TRPV4 suppresses osteoclast differentiation and osteoporosis by inhibiting autophagy through Ca
Cao B; Dai X; Wang W
J Cell Physiol; 2019 May; 234(5):6831-6841. PubMed ID: 30387123
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PPP1R15A alleviates osteoporosis via suppressing RANKL-induced osteoclastogenesis.
Ding ZB; Chen Y; Zheng YR; Wang YY; Deng WD; Zheng JH; Yang Q; Chen ZY; Li LH; Jiang H; Li XJ
Acta Pharmacol Sin; 2024 Apr; 45(4):790-802. PubMed ID: 38191913
[TBL] [Abstract][Full Text] [Related]
18. The Brown Algae
Kim M; Park M
Nutrients; 2022 Apr; 14(9):. PubMed ID: 35565651
[TBL] [Abstract][Full Text] [Related]
19. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
[TBL] [Abstract][Full Text] [Related]
20. Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway.
Tan T; Li T; Xiang C; Ouyang Z
Int Immunopharmacol; 2023 Mar; 116():109745. PubMed ID: 36702075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
